Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
bcma/gprc5d double car-t (2 trials)
bg1805 (1 trial)
cd19 car-t cells (1 trial)
cd19 universal car-γδ t cells (1 trial)
cd7 car-t cell (1 trial)
cyclophosphamide (cytoxan) (1 trial)
fludarabine (fludara) (1 trial)
cxcr5 modified egfr chimeric antigen receptor autologous t cells (1 trial)
egfr/b7h3 car-t (1 trial)
cll1-cd33 ccar t cells (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Lung Neoplasms (Phase 1)
Trials (9 total)
Trial APIs (10 total)